Thus, pharmacological inhibition of FAK activity with PF-271 or similar small molecule inhibitors will impact in Y658 VE-cadherin with important consequences in beta-catenin-derived TCF4/LEF activation of gene expression and may imply a new therapeutic opening in the overall repression of genes involved VM promotion in cancer cells. The gene discussed is TCF4; the disease is cancer.